HIV Scientific Papers
Analysis of patients completing the ibalizumab phase 3 trial and expanded access program.
2018
Cohen Z.
Oral presentation #O345 at: HIV Glasgow; October 28-31 2018; Glasgow, UK.
Pharmacokinetic profile of ibalizumab from a phase 3 trial [abstract].
2018
Open Forum Infect Dis.
Kumar PN, Weinheimer S, Cohen Z, et al.
5(suppl 1):S202. Proceedings of IDWeek, 2018.
Pharmacokinetic profile of ibalizumab from a phase 3 trial.
2018
Kumar PN, Weinheimer S, Cohen Z, et al.
Poster #544 presented at: IDWeek; October 3-7 2018; San Francisco, California, USA.
Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection [abstract].
2018
Value in Health.
Brogan AJ, Talbird SE, Davis AE, et al.
21:S12. Proceedings of the Annual Meeting of International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2018.
Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection.
2018
Brogan AJ, Talbird SE, Davis AE, et al.
Oral presentation at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 19-23 2018; Baltimore, Maryland, USA.